A phase II trial of zeniplatin in metastatic melanoma

I. Olver*, M. Green, W. Peters, A. Zimet, G. Toner, J. Bishop, W. Ketelbey, R. Rastogi, M. Birkhofer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


A third-generation platinum analogue, zeniplatin, was administered at a dose of 145 mg/m2 intravenously over 6090 minutes every 21 days as the initial chemotherapy to 21 patients with metastatic melanoma. Prehydration and mannitol diuresis was introduced after the first 7 patients. There were 17 males and 4 females. The median age was 52 (range: 29-81). ECOG performance status was 0 in 10 patients, 1 in 8 patients; and 2 in 3 patients. Major disease sites were lymph nodes, skin, lung, liver, and bone. Patients received a median of 2 cycles (range: 1-7). Two patients achieved partial responses. One with nodal disease progressed after 166 days and the either with buccal mucosal disease after 142 days. A third patient showed partial regression of nodal disease but developed cerebral metastases. Gastrointestinal toxicity included WHO grade 3 vomiting in 8 patients and nausea in 2. Antiemetics were used, but ondansetron was not available. WHO grade 3 hematologic toxicities included neutropenia in 8 patients and anemia and thrombocytopenia in 1 patient. Thrombocytosis was seen in 35% of courses. Dosage reduction was required in 15% of courses and escalation in 5% of courses. Three patients developed phlebitis related to the infusion. One patient developed a reversible rise in serum creatinine, but, unlike other studies, no severe nephrotoxicity was reported. Zeniplatin demonstrated only modest activity in melanoma with significant gastrointestinal and hematologic toxicity.

Original languageEnglish
Pages (from-to)56-58
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number1
StatePublished - 1995
Externally publishedYes


Dive into the research topics of 'A phase II trial of zeniplatin in metastatic melanoma'. Together they form a unique fingerprint.

Cite this